ADMA Biologics Inc Common Stock (ADMA)
Stock · NASDAQ · Health Care
$10.68as of 10/16/2026
Price chart
Active signals
ADMA Signal Track Record
How signals performed across all stocks →What ADMA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | +3.2% | 56% | September 18, 2026 |
| Bollinger Band Breakout | 27 | +2.2% | 52% | September 28, 2026 |
| Bollinger Band Breakdown | 21 | +1.6% | 52% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -7.1% | 22% | January 14, 2026 |
| Any 20-session window (baseline) | +2.7% | 55% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ADMA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatmen…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 640
- Website
- www.admabiologics.com/
Fundamentals
- 1-day range
- $9.25$10.17
- Market cap
- $2.34B
- P/E (trailing)
- 13.67
- P/E (forward)
- 10.73
- EPS (trailing)
- $0.71
- Dividend yield
- —
- Beta
- 0.70
- Avg. volume
- 2.62M
How ADMA Biologics Inc Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
ADMA Biologics Inc Common Stock Competitors
Chosen by industry and closest market cap.
- ADMAADMA Biologics Inc Common Stock$10.68▼ 0.47%Market cap $2.34BP/E 13.67$7.21$20.46
- BCRXBioCryst Pharmaceuticals Inc. Common Stock$7.79▼ 2.87%Market cap $2.36BP/E —$6.23$11.22
- VCELVericel Corporation Common Stock$40.13▼ 2.17%Market cap $2.29BP/E 85.09$28.95$49.32
- RVMDWRevolution Medicines Inc. Warrant$8.4▼ 13.98%Market cap $2.25BP/E —$0.2311$13.44
- MESOMesoblast Limited American Depositary Shares$13.28▼ 4.80%Market cap $2.02BP/E —$1.88$3.31
- IOVAIovance Biotherapeutics Inc. Common Stock$13.62▼ 7.47%Market cap $2.77BP/E —$1.76$15.3
- TARSTarsus Pharmaceuticals Inc. Common Stock$68.07▼ 4.11%Market cap $2.81BP/E —$53.89$91.53
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ADMA ADMA Biologics Inc Common Stock | $2.34B | 13.67 | $10.68 | ▼ 0.47% | $7.21$20.46 |
| BCRX BioCryst Pharmaceuticals Inc. Common Stock | $2.36B | — | $7.79 | ▼ 2.87% | $6.23$11.22 |
| VCEL Vericel Corporation Common Stock | $2.29B | 85.09 | $40.13 | ▼ 2.17% | $28.95$49.32 |
| RVMDW Revolution Medicines Inc. Warrant | $2.25B | — | $8.4 | ▼ 13.98% | $0.2311$13.44 |
| MESO Mesoblast Limited American Depositary Shares | $2.02B | — | $13.28 | ▼ 4.80% | $1.88$3.31 |
| IOVA Iovance Biotherapeutics Inc. Common Stock | $2.77B | — | $13.62 | ▼ 7.47% | $1.76$15.3 |
| TARS Tarsus Pharmaceuticals Inc. Common Stock | $2.81B | — | $68.07 | ▼ 4.11% | $53.89$91.53 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 209.07M
- Total value held
- $1.82B
- Institutional holders
- 350
- Unknown36.83M
- Unknown14.08M
- Unknown11.19M
- Unknown10.31M
- Unknown6.25M
- Unknown6.10M
- Unknown5.82M
- Unknown5.06M
- Unknown5.01M
- Unknown4.79M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ADMA Biologics Draws Investor Attention Amid Market Decline
Recent reports indicate that ADMA Biologics is attracting investor attention and showing relative strength while the broader market declines. Analysts have expressed optimism, with an average price target of $17.00, which is well above the current trading range. This suggests that some market participants view the stock as undervalued relative to its long-term potential, despite recent volatility.
ADMA Biologics Draws Investor Attention Amid Market Decline. Recent reports indicate that ADMA Biologics is attracting investor attention and showing relative strength while the broader market declines. Analysts have expressed optimism, with an average price target of $17.00, which is well above the current trading range. This suggests that some market participants view the stock as undervalued relative to its long-term potential, despite recent volatility.